Design of Long-acting GLP-1 Analogs Applicable for Once Weekly and Oral Dosing

09:30 - 10:05

  • The discovery journey towards once week semaglutide
  • Preclinical and clinical data
  • The ambitious challenge to oral delivery of semaglutide

Jesper Lau, Vice President, Protein and Peptide Chemistry, Novo Nordisk